Current status of PSA screening. Early detection of prostate cancer

Canadian Family Physician

Volumn 50, Issue JAN., 2004, Pages 57-63

  Pickles, Tom ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANADA; CANCER MORTALITY; CANCER PATIENT; CANCER SCREENING; CANCER SURVIVAL; CLINICAL STUDY; DECISION MAKING; EARLY DIAGNOSIS; HUMAN; LIFE EXPECTANCY; MALE; MEDLINE; PROSTATE CANCER; WESTERN HEMISPHERE;

AGED; DIAGNOSIS, DIFFERENTIAL; EVIDENCE-BASED MEDICINE; HUMANS; LIFE EXPECTANCY; MALE; MASS SCREENING; MIDDLE AGED; PATIENT EDUCATION; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; SURVIVAL ANALYSIS;

EID: 1642514902     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Canadian Cancer Society. Canadian cancer statistics, 2002. Toronto, Ont: National Cancer Institute of Canada; 2002. Available at: http://www.cancer.ca. Accessed 2003 October 30.
2. Mercer SL, Goel V, Levy IG, Ashbury FD, Iverson DC, Iscoe NA. Prostate cancer screening in the midst of controversy: Canadian men's knowledge, beliefs, utilization, and future intentions. Can J Public Health 1997;88(5):327-32.
3. Bunting PS, Goel V, Williams JI, Iscoe NA. Prostate-specific antigen testing in Ontario: reasons for testing patients without diagnosed prostate cancer. CMAJ 1999;160(1):70-5.
4. Wilson J, Jugner G. Principles and practice of screening for disease. Bol Oficina Sanit Panan 1968;65(4):281-393.
5. Holmberg L, Bill-Axelson A, Helgesen F, Salo JO, Folmerz P, Haggman M, et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 2002;347(11):781-9.
6. Sakr WA, Haas GP, Cassin BF, Pontes JE, Crissman JD. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol 1993;150(2 Pt 1):379-85.
7. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349(3):215-24.
8. Pickles T, Coldman A, Phillips N. The changing face of prostate cancer in British Columbia 1988-2000. Can J Urol 2002;9(3):1551-7.
9. Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 1995;273(4):289-94.
10. Auvinen A, Rietbergen JB, Denis LJ, Schroder FH, Prorok PC. Prospective evaluation plan for randomised trials of prostate cancer screening. The International Prostate Cancer Screening Trial Evaluation Group. J Med Screen 1996;3(2):97-104.
11. National Cancer Institute. Prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. Bethesda, Md: National Cancer Institute; 2003. Available at: http://www3.cancer.gov/prevention/plco/. Accessed 2003 October 30.
12. Van der Cruijsen-Koeter I, Roobol M, Damhuis R, De Koning H, Schroeder F. Comparison of screen detected and clinically diagnosed prostate cancer in the European randomized study of screening for prostate cancer. American Urological Association Annual Meeting in Anaheim, Cal. J Urol 2002;4(Suppl):102. Abstract 407.
13. Maattanen L, Auvinen A, Stenman UH, Rannikko S, Tammela T, Aro J, et al. European randomized study of prostate cancer screening: first-year results of the Finnish trial. Br J Cancer 1999;79(7-8):1210-4.
14. Labrie F, Candas B, Dupont A, Cusan L, Gomez JL, Suburu RE, et al. Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial [see comments]. Prostate 1999;38(2):83-91.
15. Boer R, Schroder FH. Quebec randomized controlled trial on prostate cancer screening shows no evidence for mortality reduction. Prostate 1999;40(2):130-4.
16. Alexander FE, Prescott RJ. Reply to Labrie et al. Results of the mortality analysis of the Quebec randomized controlled trial (RCT). Prostate 1999;40(2):135-7.
17. NHS Centre for Reviews and Dissemination. Screening for prostate cancer. York, Engl: NHS Centre for Reviews and Dissemination; 1997. Available at: http://www.york.ac.uk/inst/crd/em22a. Accessed 2003 October 30.
18. Lu-Yao G, Albertsen PC, Stanford JL, Stukel TA, Walker-Corkery ES, Barry MJ. Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. BMJ 2002;325(7367):740-6.
19. Oliver SE, May MT, Gunnell D. International trends in prostate-cancer mortality in the "PSA Era". Int J Cancer 2001;92(6):893-8.
20. Perron L, Moore L, Bairati I, Bernard PM, Meyer F. PSA screening and prostate cancer mortality. CMAJ 2002;166(5):586-91.
21. Coldman A, Phillips N, Pickles T. Trends in prostate cancer incidence and mortality: an analysis of mortality change by screening intensity. CMAJ 2003;168(1):31-5.
22. Bartsch G, Horninger W, Klocker H, Reissigl A, Oberaigner W, Schonitzer D, et al. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology 2001;58(3):417-24.
23. Boyle P, Horninger W, Oberainger W, Schonitzer D, Severi G, Robertson C, et al. Prostate cancer mortality in Tyrol, Austria. Update to year 2000. American Urological Association Annual Meeting in Orlando, Fla. J Urol 2002;4(Suppl):102. Abst 406.
24. Agency for Healthcare Research and Quality. Screening for prostate cancer. Rockville, Md: Agency for Healthcare Research and Quality; 2000. Available at: http://www.ahrq.gov/clinic/uspstf/uspsprca.htm. Accessed 2003 Dec 8.
25. NHS Cancer Screening Programmes, Prostate cancer risk management. Sheffield, UK: National Health Service; 2002, Available at: http://www.cancerscreening.nhs.uk/prostate. Accessed 2003 October 30.
26. Chapple A, Ziebland S, Shepperd S, Miller R, Herxheimer A, McPherson A. Why men with prostate cancer want wider access to prostate specific antigen testing: qualitative study. BMJ 2002;325(7367):737-41.
27. Chodak GW. Screening for prostate cancer. Eur Urol 1993;24(Suppl 2):3-5.
28. Chan EC, Sulmasy DP. What should men know about prostate-specific antigen screening before giving informed consent? Am J Med 1998;105(4):266-74.
29. Ross KS, Carter HB, Pearson JD, Guess HA. Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection. JAMA 2000;284(11):1399-405.
30. Crawford D, Chia D, Andriole GL, Reding D, Gelmann E, Gohagan P, et al. PSA testing interval, reduction in screening intervals: Data from the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) screening trial. American Urological Association Annual Meeting in Orlando, Fla. J Urol 2002;4(Suppl):99. Abst 397.